Notice of completion of participant enrollment in the additional Phase III clinical trial of the functional peptide “SR-0379”
FunPep Company Limited (the Company)
Functional peptide “SR-0379” / additional Phase III clinical trial (SR0379-JP-SU-02 trial, Trial 02) / skin ulcers
No impact on results for the fiscal year ending December 2026 (impact amount: Not disclosed)
Fiscal year ending December 2026 (no impact on results)
No impact on the FunPep Group’s results for the fiscal year ending December 2026
Results will be evaluated after all participants have completed the treatment and observation periods. Preliminary results are expected to be disclosed in the first half of 2027 (January to June).
| Item | Details |
|---|---|
| Event name | Notice of completion of participant enrollment in the additional Phase III clinical trial of the functional peptide “SR-0379” |
| Subject Entity | FunPep Company Limited (the Company) |
| Target Locations / Products | Functional peptide “SR-0379” / additional Phase III clinical trial (SR0379-JP-SU-02 trial, Trial 02) / skin ulcers |
| Amount of Impact on Business Performance | No impact on results for the fiscal year ending December 2026 (impact amount: Not disclosed) |
| Accounting period in which recognized | Fiscal year ending December 2026 (no impact on results) |
| Impact on Earnings Forecast | No impact on the FunPep Group’s results for the fiscal year ending December 2026 |
| Outlook | Results will be evaluated after all participants have completed the treatment and observation periods. Preliminary results are expected to be disclosed in the first half of 2027 (January to June). |
| Planned follow-up disclosure | Preliminary results are expected to be disclosed in the first half of 2027 (January to June). |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The number of participants administered the investigational drug reached 143, meeting the target number of participants.